The new GWAS sample includes 1,221 cases from STAR*D, a multi-center, NIMH-sponsored antidepressant clinical trial.7, 8 The GenRED GWAS4 included 1,020 cases, with 1,636 controls from the Molecular Genetics of Schizophrenia (MGS) study9 (excluding controls who reported any history of MDD). The STAR*D analysis uses the same control data, and our meta-analysis corrects for that overlap. We accessed the GAIN-MDD dataset and carried out a new analysis (for methodological consistency) of 1,715 cases and 1,792 controls, slightly smaller than the published sample5 but with very similar results.
